{
    "clinical_study": {
        "@rank": "121093", 
        "arm_group": [
            {
                "arm_group_label": "Arm 1", 
                "arm_group_type": "Experimental", 
                "description": "ABT-493 Dose A for 3 days, followed by ABT-450/r/ABT-267 and ABT-333 coadministered with ribavirin (RBV) for 12 or 24 weeks"
            }, 
            {
                "arm_group_label": "Arm 2", 
                "arm_group_type": "Experimental", 
                "description": "ABT-493 Dose B for 3 days, followed by ABT-450/r/ABT-267 and ABT-333 coadministered with ribavirin (RBV) for 12 or 24 weeks"
            }, 
            {
                "arm_group_label": "Arm 3", 
                "arm_group_type": "Experimental", 
                "description": "ABT-493 Dose C for 3 days, followed by ABT-450/r/ABT-267 and ABT-333 coadministered with ribavirin (RBV) for 12 or 24 weeks"
            }, 
            {
                "arm_group_label": "Arm 4", 
                "arm_group_type": "Experimental", 
                "description": "ABT-493 Dose D for 3 days, followed by ABT-450/r/ABT-267 and ABT-333 coadministered with ribavirin (RBV) for 12 or 24 weeks"
            }, 
            {
                "arm_group_label": "Arm 5", 
                "arm_group_type": "Experimental", 
                "description": "ABT-493 Dose E for 3 days, followed by ABT-450/r/ABT-267 and ABT-333 coadministered with ribavirin (RBV) for 12 or 24 weeks"
            }, 
            {
                "arm_group_label": "Arm 6", 
                "arm_group_type": "Experimental", 
                "description": "ABT-530 Dose A for 3 days, followed by ABT-450/r/ABT-267 and ABT-333 coadministered with ribavirin (RBV) for 12 or 24 weeks"
            }, 
            {
                "arm_group_label": "Arm 7", 
                "arm_group_type": "Experimental", 
                "description": "ABT-530 Dose B for 3 days, followed by ABT-450/r/ABT-267 and ABT-333 coadministered with ribavirin (RBV) for 12 or 24 weeks"
            }, 
            {
                "arm_group_label": "Arm 8", 
                "arm_group_type": "Experimental", 
                "description": "ABT-530 Dose C for 3 days, followed by ABT-450/r/ABT-267 and ABT-333 coadministered with ribavirin (RBV) for 12 or 24 weeks"
            }, 
            {
                "arm_group_label": "Arm 9", 
                "arm_group_type": "Experimental", 
                "description": "ABT-530 Dose D for 3 days, followed by ABT-450/r/ABT-267 and ABT-333 coadministered with ribavirin (RBV) for 12 or 24 weeks"
            }, 
            {
                "arm_group_label": "Arm 10", 
                "arm_group_type": "Experimental", 
                "description": "ABT-530 Dose E for 3 days, followed by ABT-450/r/ABT-267 and ABT-333 coadministered with ribavirin (RBV) for 12 or 24 weeks"
            }, 
            {
                "arm_group_label": "Arm 11", 
                "arm_group_type": "Experimental", 
                "description": "ABT-493 Dose F for 3 days, followed by ABT-450/r/ABT-267 and ABT-333 coadministered with ribavirin (RBV) for 12 or 24 weeks"
            }, 
            {
                "arm_group_label": "Arm 12", 
                "arm_group_type": "Experimental", 
                "description": "ABT-530 Dose F for 3 days, followed by ABT-450/r/ABT-267 and ABT-333 coadministered with ribavirin (RBV) for 12 or 24 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety and antiviral effect of multiple doses\n      of ABT-493 and ABT-530 in adults with genotype 1 HCV."
        }, 
        "brief_title": "A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV)", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Chronic Hepatitis C", 
            "Hepatitis C Virus", 
            "Compensated Cirrhosis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis, Chronic", 
                "Hepatitis C", 
                "Liver Cirrhosis", 
                "Fibrosis", 
                "Virus Diseases", 
                "Hepatitis C, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Chronic HCV infection prior to study enrollment.\n\n          -  Screening laboratory result indicating HCV genotype 1-infection.\n\n          -  Subject has plasma HCV RNA level greater than 10,000 IU/mL at Screening.\n\n          -  Per local standard, subject is considered to be non-cirrhotic or to have compensated\n             cirrhosis.\n\n        Exclusion Criteria:\n\n          -  History of severe, life-threatening or other significant sensitivity to any drug.\n\n          -  Positive test result for Hepatitis B surface antigen (HBsAg) or anti-Human\n             Immunodeficiency Virus antibody (HIV Ab).\n\n          -  Prior therapy for the treatment of HCV.\n\n          -  Any current or past clinical evidence of Child Pugh B or C classification of clinical\n             history of liver decompensation including ascites (noted on physical exam), variceal\n             bleeding or hepatic encephalopathy.\n\n          -  Any cause of liver disease other than chronic HCV infection."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "96", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01995071", 
            "org_study_id": "M13-595"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Arm 1", 
                    "Arm 2", 
                    "Arm 3", 
                    "Arm 4", 
                    "Arm 5", 
                    "Arm 11"
                ], 
                "description": "tablet", 
                "intervention_name": "ABT-493", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Arm 6", 
                    "Arm 7", 
                    "Arm 8", 
                    "Arm 9", 
                    "Arm 10", 
                    "Arm 12"
                ], 
                "description": "tablet", 
                "intervention_name": "ABT-530", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Arm 1", 
                    "Arm 2", 
                    "Arm 3", 
                    "Arm 4", 
                    "Arm 5", 
                    "Arm 6", 
                    "Arm 7", 
                    "Arm 8", 
                    "Arm 9", 
                    "Arm 10", 
                    "Arm 11", 
                    "Arm 12"
                ], 
                "description": "tablet", 
                "intervention_name": "ABT-450/r/ABT-267", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Arm 1", 
                    "Arm 2", 
                    "Arm 3", 
                    "Arm 4", 
                    "Arm 5", 
                    "Arm 6", 
                    "Arm 7", 
                    "Arm 8", 
                    "Arm 9", 
                    "Arm 10", 
                    "Arm 11", 
                    "Arm 12"
                ], 
                "description": "tablet", 
                "intervention_name": "ABT-333", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Arm 1", 
                    "Arm 2", 
                    "Arm 3", 
                    "Arm 4", 
                    "Arm 5", 
                    "Arm 6", 
                    "Arm 7", 
                    "Arm 8", 
                    "Arm 9", 
                    "Arm 10", 
                    "Arm 11", 
                    "Arm 12"
                ], 
                "description": "tablet", 
                "intervention_name": "Ribavirin (RBV)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Antiviral Agents", 
                "Ribavirin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Chronic Hepatitis C", 
            "Cirrhosis", 
            "Child Pugh A", 
            "Hepatitis C virus", 
            "Compensated Cirrhosis", 
            "Hepatitis C Genotype 1", 
            "Hepatitis C", 
            "Interferon-Free", 
            "Cirrhotic"
        ], 
        "lastchanged_date": "April 22, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Phoenix", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85054"
                    }, 
                    "name": "Site Reference ID/Investigator# 119692"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chula Vista", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91911"
                    }, 
                    "name": "Site Reference ID/Investigator# 120958"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Bernardino", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92404"
                    }, 
                    "name": "Site Reference ID/Investigator# 123766"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92120"
                    }, 
                    "name": "Site Reference ID/Investigator# 120955"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92120"
                    }, 
                    "name": "Site Reference ID/Investigator# 120956"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92161"
                    }, 
                    "name": "Site Reference ID/Investigator# 119719"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92120"
                    }, 
                    "name": "Site Reference ID/Investigator# 123058"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Aurora", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80045"
                    }, 
                    "name": "Site Reference ID/Investigator# 119680"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32803"
                    }, 
                    "name": "Site Reference ID/Investigator# 119678"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32809"
                    }, 
                    "name": "Site Reference ID/Investigator# 119687"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30308"
                    }, 
                    "name": "Site Reference ID/Investigator# 119695"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46202-5121"
                    }, 
                    "name": "Site Reference ID/Investigator# 119685"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21202"
                    }, 
                    "name": "Site Reference ID/Investigator# 119691"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kansas City", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "64131"
                    }, 
                    "name": "Site Reference ID/Investigator# 123765"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Manhasset", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "11030"
                    }, 
                    "name": "Site Reference ID/Investigator# 119676"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10016"
                    }, 
                    "name": "Site Reference ID/Investigator# 119690"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78215"
                    }, 
                    "name": "Site Reference ID/Investigator# 119686"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Murray", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84123"
                    }, 
                    "name": "Site Reference ID/Investigator# 119677"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98101"
                    }, 
                    "name": "Site Reference ID/Investigator# 119683"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "12", 
        "official_title": "A Randomized, Open-Label, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-493 and ABT-530 in Adult Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection", 
        "overall_official": {
            "affiliation": "AbbVie", 
            "last_name": "Armen  Asatryan, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Maximal decrease in log10 hepatitis C virus ribonucleic acid levels from baseline", 
            "safety_issue": "No", 
            "time_frame": "3 days after first dose of study drug"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01995071"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Hepatitis C virus ribonucleic acid less than the lower limit of quantification", 
                "measure": "The percentage of subjects with sustained virologic response 12 weeks post-treatment", 
                "safety_issue": "No", 
                "time_frame": "12 weeks after last dose of study drug"
            }, 
            {
                "description": "Percentage of subjects with quantifiable hepatitis C virus ribonucleic acid throughout the entire treatment period, confirmed quantifiable hepatitis C virus ribonucleic acid after previously having unquantifiable hepatitis C virus ribonucleic acid, or a confirmed increase of at least one log10 in hepatitis C virus ribonucleic acid during treatment", 
                "measure": "The percentage of subjects with on-treatment virologic failure during the treatment period", 
                "safety_issue": "No", 
                "time_frame": "Up to 171 days"
            }, 
            {
                "description": "Percentage of subjects with confirmed quantifiable hepatitis C virus ribonucleic acid among subjects with unquantifiable hepatitis C virus ribonucleic acid at the end of treatment", 
                "measure": "The percentage of subjects with post-treatment relapse", 
                "safety_issue": "No", 
                "time_frame": "Within 12 weeks after the last dose of study drug"
            }
        ], 
        "source": "AbbVie", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AbbVie", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}